Consider the following medical report that includes the patient's historical health records. Use it to predict the disease that the patient is high likely exposed to. 

 Medical Report: allergies: demerol / ifosfamide attending: chief complaint: scheduled admission for ice w/ ofatumumab chemotherapy major surgical or invasive procedure: chemotherapy history of present illness: ms. is a 74-year-old woman with recurrent follicular cell lymphoma who presents for induction with ofatumumab with ice chemotherapy as part of a phase ii study. she was initially diagnosed in and received r-chop therapy in . she was in remission until this month when she had a restaging ct scan because of an elevated creatinine. she was found to have a large right pelvic sidewall mass obstructing her ureter and multiple enlarged lymph nodes. she had a stent placed in her right ureter. biopsy showed recurrence of her grade 3b follicular cell lymphoma. she has since been found to have a rising ldh and hypercalcemia, and decided with her local oncologist, dr. , to enter into a study protocol #df 09-111, "safety and efficacy study of ofatumumab in combination with ice or dhap chemotherapy in relapsed or refractory aggressive lymphoma prior to autologous stem cell transplantation." . she has recently felt well except for somewhat decreased energy and a 5lb weight loss. she has pain when using her right shoulder from a rotator cuff tear that she chose not to repair. she has had rhinorrhea since her ureteral stent placement two weeks ago. she denies fever, chills or night sweats. despite her rhinorrhea, she denies headache, sinus tenderness or congestion. denies chest pain or tightness, palpitations. denies cough, shortness of breath, or wheezes. denied nausea, vomiting, diarrhea, constipation or abdominal pain. no recent change in bowel or bladder habits. no dysuria. denies arthralgias or myalgias. denies rashes or skin breakdown. past medical history: oncologic history: was diagnosed in with a grade 3b follicular lymphoma after being noted to have hypercalcemia (18) and bulky lymphadenopathy. biopsy of a left inguinal node showed grade 3b follicular lymphoma with a mib of 50-60%, and she was treated with 6 cycles of r-chop completing therapy in . pet scan was negative at the completion of chemotherapy and her most recent prior ct scan was done in and also was negative for disease relapse. however, in early , she underwent restaging ct done without contrast because of an elevated creatinine and she was found to have a large right pelvic sidewall mass (6.5 x 3.1 cm) causing obstruction of her ureter causing right hydronephrosis. there was some soft tissue thickening along the posterior right lateral aspect of her bladder, a left pelvic side wall mass that was 2.8 cm, a right paraaortic lymph node that was 2.1 cm, a left paraaortic lymph node at 1.2 cm, and some left external iliac and inguinal lymphadenopathy as well as some other enlarged mesenteric lymph nodes. she underwent ultrasound-guided biopsy again of a left inguinal lymph node, which again showed a grade 3 follicular lymphoma. her ldh and calcium had been within normal limits at previous oncologist visit, and she was sent here for further evaluation and consideration of autologous stem cell transplant. at presentation on she developed hypercalcemic with a calcium of 11.4 an elevated ldh. she followed up locally with dr. for labs and zometa while decided whether or not to pursue treatment at . . past medical history: significant for hypertension, osteopenia, and endometriosis. . past surgical history: status post tonsillectomy and adenoidectomy in , status post appendectomy at age 42, status post tah with bso in , and status post right knee arthroscopy. social history: lives alone. she never married. she has a 48-year-old son who lives in and three grandchildren. she worked in administrative positions in healthcare facilities, but is currently retired. she does not smoke. she drinks alcohol rarely, perhaps one drink a month. family history: her mother is deceased at age , she unsure of the cause. her father is deceased at age 77 from a brain tumor. she had a brother who is deceased from heart disease and a paternal cousin who is deceased from lung cancer. her son has no medical problems and she knows of no other cancer or blood disorder in the family. physical exam: gen: pleasant, lying down in no acute distress, wt 142.8lbs, ht 65" vs: t 98.8 bp 108/68 hr 92 rr 18 o2 96% ra heent: ncat, eomi, perrl, sclera anicteric, mmm, oropharynx clear, neck supple, no jvd, no thyromegaly. cv: rrr, normal s1 and s2, no m/r/g pulm: ctab abd: +bs, soft, non-tender, non-distended with no palpable masses. limbs: warm, well-perfused, 2+ radial and dp pulses, no edema. skin: dry skin on legs, no rashes. neuro: a&ox3, 5/5 strength throughout pertinent results: lab results on admission: 09:30am blood wbc-6.4 rbc-3.35* hgb-9.6* hct-27.9* mcv-83 mch-28.6 mchc-34.4 rdw-13.7 plt ct-100* 09:30am blood neuts-80* bands-0 lymphs-7* monos-4 eos-2 baso-0 atyps-0 metas-0 myelos-0 other-7* 09:30am blood hypochr-normal anisocy-normal poiklo-normal macrocy-normal microcy-normal polychr-occasional ovalocy-occasional tear dr 09:30am blood plt smr-low plt ct-100* 09:30am blood gran ct-5120 09:30am blood cd5-done cd23-done cd45-done hla-dr 7-done kappa-done cd10-done cd19-done cd20-done lambda-done 09:30am blood cd3%-done 09:30am blood glucose-91 urean-14 creat-0.8 na-141 k-3.8 cl-105 hco3-23 angap-17 09:30am blood alt-45* ast-49* ld(ldh)-545* alkphos-95 totbili-0.4 09:30am blood albumin-3.4 calcium-10.0 uricacd-6.3* . lab results on discharge: 12:00am blood wbc-0.3*# rbc-3.18* hgb-9.0* hct-26.0* mcv-82 mch-28.2 mchc-34.5 rdw-14.5 plt ct-61* 12:00am blood neuts-78* bands-0 lymphs-14* monos-0 eos-2 baso-4* atyps-2* metas-0 myelos-0 12:00am blood hypochr-normal anisocy-normal poiklo-occasional macrocy-normal microcy-normal polychr-normal ovalocy-occasional tear dr 12:00am blood plt ct-61* 12:00am blood gran ct-100* 12:00am blood glucose-98 urean-25* creat-1.2* na-140 k-3.8 cl-112* hco3-17* angap-15 12:00am blood alt-42* ast-36 ld(ldh)-367* alkphos-71 totbili-0.8 12:00am blood albumin-3.3* calcium-9.3 phos-2.1* mg-1.9 . brief hospital course: ms. was admitted on for induction with ofatumumab/ice chemotherapy as part of a phase ii study. . # ifosphamide toxicity ms. features of ifosphamide nephrotoxicity and neurological side-effects of confusion, delerium and aphasia. other causes of these neurological phenomena were ruled out. ifosphamide toxicity was treated with methylene blue and with repletion of potassium and phosphorous (in the of renal tubular acidosis). the adequacy of potassium and phosphate supplementation is an important issue for her continuing care. . # hypertension lisinopril and atenolol were held during the admission. metoprolol was used during the admission, and ms. was discharged with her usual dose of atenolol alone. lisinopril was held in the context of acute renal failure, which resolved over the admission. this is an important issue for follow-up. . # acute renal insufficiency. resulted in holding of lisinopril, which can be re-started with due consideration of recovering renal insufficiency and need for supplementary potassium. this transient increase in creatine from baseline 0.9 is attributed to contrast while working up mental status changes. this is trending down. renal tubular acidosis resulted from ifosphamide as above. . # neutropenia. to be treated in with neupogen. this will be followed by dr. at , with an appointment scheduled for monday. . medications on admission: allopurinol 100 mg by mouth once a day atenolol 50 mg by mouth once a day lisinopril 20 mg tablet by mouth once a day discharge medications: 1. acyclovir 200 mg capsule sig: two (2) capsule po q8h (every 8 hours). disp:*3 capsule(s)* refills:*2* 2. potassium chloride 20 meq tab sust.rel. particle/crystal sig: two (2) tab sust.rel. particle/crystal po once a day. disp:*14 tab sust.rel. particle/crystal(s)* refills:*2* 3. phospha 250 neutral 250 mg tablet sig: two (2) tablet po three times a day. disp:*42 tablet(s)* refills:*2* 4. atenolol 50 mg tablet sig: one (1) tablet po once a day. 5. outpatient lab work please check potassium, phosphate and creatinine. 6. filgrastim 300 mcg/0.5 ml syringe sig: one (1) injection once a day for 4 days: please give through . to be given at clinic. . disp:*4 doses* refills:*0* discharge disposition: home discharge diagnosis: lymphoma (follicular cell) discharge condition: good, alert and oriented to person, place and date, hemodynamically stable. discharge instructions: you were admitted for scheduled chemotherapy. during the admission you had a neurologic reaction to one of the chemotherapies (ifosphamide). you required a medication called methylene blue and your neurologic status improved to your baseline. you had several radiology studies (cat scan and mri) of your brain that were normal. in addition, this , ifosphamide, alterned your renal function, requiring two of the medicines that you will take at home. . the following changes have been made to your home medications: you will continue your home atenolol. you will stop allopurinol. you will stop lisinopril. you should discuss with your oncologist on monday when to resume lisinopril. you will start acyclovir. you have been started on potassium and phosphate supplements. you will discuss with your oncologist when to stop taking these. you have been started on neupogen which you will continue to get at dr office. please take all medications as directed below. . please attend your follow up appointments. . if you develop fever, chills, nausea, vomiting, or any other concerning symptoms, please call your oncologist, or go to the emergency room. followup instructions: you are scheduled to go to dr office on thursday, at 2pm where you will have a neupogen injection and they will check your electrolytes. . you will follow up with dr on monday, at 9am in 7 feldburg. procedure: injection or infusion of cancer chemotherapeutic substance diagnoses: acidosis toxic encephalopathy unspecified essential hypertension acute kidney failure, unspecified pneumonitis due to inhalation of food or vomitus antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use hydronephrosis drug induced neutropenia examination of participant in clinical trial other specified disorders resulting from impaired renal function nodular lymphoma, unspecified site, extranodal and solid organ sites encounter for antineoplastic chemotherapy 

Answer: The patient is high likely exposed to